SCHEMBL25201614

SCHEMBL25201614

COc1ccc(C(=O)C(C)CO)c(O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.60
RAB9A P51151 5/20 0.60
CYP3A4 P08684 5/20 0.58
HPGD P15428 4/20 0.58
ALDH1A1 P00352 3/20 0.58
MAPK1 P28482 3/20 0.58
KMT2A Q03164 6/20 0.57
MEN1 O00255 5/20 0.57
MAPT P10636 4/20 0.57
PPARG P37231 1/20 0.57
LMNA P02545 4/20 0.53
CYP2C19 P33261 3/20 0.53
CYP1A2 P05177 2/20 0.53
PGR P06401 2/20 0.53
SLC6A2 P23975 2/20 0.53
ADORA3 P0DMS8 1/20 0.53
AR P10275 1/20 0.53
CHRM1 P11229 1/20 0.53
ALOX15 P16050 1/20 0.53
TBXA2R P21731 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3639792 0.83 NPC1 (0.68) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL30251391 0.82 NPC1 (0.57) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL30251172 0.82 NPC1 (0.57) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL23882642 0.82 NPC1 (0.57) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL5477586 0.78 NPC1 (0.70) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL9405712 0.77 CYP3A4 (0.52) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL9405714 0.77 CYP3A4 (0.52) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL30251439 0.76 NPC1 (0.50) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL28047855 0.76 NPC1 (0.62) NPC1RAB9ACYP3A4HPGDALDH1A1
SCHEMBL29365072 0.76 NPC1 (1.00) NPC1RAB9ACYP3A4HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126835-B1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 EP disclosed
US-12516038-B2 Inhibitors of antigen presentation by HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-01-06 US disclosed
US-20230150985-A1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2023-05-18 US disclosed
EP-4126835-A1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR Janssen Pharmaceutica NV (BE) 2023-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150985-A1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR HLA-DRB1, CD74, HLA-C NPC1 196/4885RAB9A 2175/4885CYP3A4 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.